Atlas Trials

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Clinical trial NCT05824390 · UNKNOWN

Trial details

NCT number
NCT05824390
Sponsor
XIEJINGYUAN
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
IgA Nephropathy
Start date
2020-06-20
Primary completion
2023-10-01
Enrollment
116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.